{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:04:25Z","timestamp":1779879865678,"version":"3.53.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T00:00:00Z","timestamp":1533686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T00:00:00Z","timestamp":1533686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2006.093.1"],"award-info":[{"award-number":["2006.093.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2006.093.1"],"award-info":[{"award-number":["2006.093.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2006.093.1"],"award-info":[{"award-number":["2006.093.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated the functional role of CEACAM1 in a spontaneous metastasis xenograft model of human melanoma in scid mice using BRAF wildtype MeWo cells with and without RNAi mediated knockdown of CEACAM1. Tumors from the xenograft model were subjected to whole genome expression analysis and metastasis was quantified histologically. Results and identified markers were verified using tissue samples of over 100 melanoma patients. Knockdown of CEACAM1 prolonged the animals\u2019 survival by significantly reducing subcutaneous growth of MeWo tumors and spontaneous lung metastasis. Microarray analysis revealed a strong influence of CEACAM1 knockdown on the network of EMT associated genes in the xenograft tumors (e.g. downregulation of BRAF, FOSL1, NRAS and TWIST). IGFBP7 and Latexin (highest up- and downregulated expression in microarray analysis) were found to be associated with longer and shorter survival, respectively, of melanoma patients. High FOSL1 and altered TWIST1 expression were found to be correlated with shortened survival in the cohort of melanoma patients. After a stepwise selection procedure combining above markers, multivariate analysis revealed IGFBP7, Latexin and altered TWIST to be prognostic markers for death. CEACAM1 could be a target for melanoma therapy as an alternative to (or in combination with) immune checkpoint and BRAF inhibitors.<\/jats:p>","DOI":"10.1038\/s41598-018-30338-4","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T13:36:50Z","timestamp":1533217010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells"],"prefix":"10.1038","volume":"8","author":[{"given":"Daniel","family":"Wicklein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Suling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Elies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"L\u00fcers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Feldhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Maar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schr\u00f6der-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,8]]},"reference":[{"key":"30338_CR1","doi-asserted-by":"crossref","unstructured":"van Zeijl, M. C., van den Eertwegh, A. J., Haanen, J. B. & Wouters, M. W. (Neo)adjuvant systemic therapy for melanoma. Eur J Surg Oncol (2016).","DOI":"10.1016\/j.ejso.2016.07.001"},{"key":"30338_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364, 2507\u20132516 (2011).","journal-title":"N Engl J Med"},{"key":"30338_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358\u2013365 (2012).","journal-title":"Lancet"},{"key":"30338_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","volume":"32","author":"N Beauchemin","year":"2013","unstructured":"Beauchemin, N. & Arabzadeh, A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer metastasis reviews 32, 643\u2013671 (2013).","journal-title":"Cancer metastasis reviews"},{"key":"30338_CR5","doi-asserted-by":"publisher","first-page":"10744","DOI":"10.1073\/pnas.90.22.10744","volume":"90","author":"M Neumaier","year":"1993","unstructured":"Neumaier, M., Paululat, S., Chan, A., Matthaes, P. & Wagener, C. Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc Natl Acad Sci USA 90, 10744\u201310748 (1993).","journal-title":"Proc Natl Acad Sci USA"},{"key":"30338_CR6","first-page":"3203","volume":"18","author":"J Huang","year":"1998","unstructured":"Huang, J. et al. Expression of biliary glycoprotein (CD66a) in normal and malignant breast epithelial cells. Anticancer Res 18, 3203\u20133212 (1998).","journal-title":"Anticancer Res"},{"key":"30338_CR7","first-page":"2375","volume":"11","author":"T Kunath","year":"1995","unstructured":"Kunath, T., Ordonez-Garcia, C., Turbide, C. & Beauchemin, N. Inhibition of colonic tumor cell growth by biliary glycoprotein. Oncogene 11, 2375\u20132382 (1995).","journal-title":"Oncogene"},{"key":"30338_CR8","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1158\/0008-5472.CAN-04-0505","volume":"64","author":"L Oliveira-Ferrer","year":"2004","unstructured":"Oliveira-Ferrer, L. et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res 64, 8932\u20138938 (2004).","journal-title":"Cancer Res"},{"key":"30338_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.prp.2009.01.006","volume":"205","author":"CJ Zhou","year":"2009","unstructured":"Zhou, C. J. et al. The different expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and possible roles in gastric carcinomas. Pathol Res Pract 205, 483\u2013489 (2009).","journal-title":"Pathol Res Pract"},{"key":"30338_CR10","doi-asserted-by":"publisher","first-page":"e113023","DOI":"10.1371\/journal.pone.0113023","volume":"9","author":"F Gebauer","year":"2014","unstructured":"Gebauer, F. et al. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. PLoS One 9, e113023 (2014).","journal-title":"PLoS One"},{"key":"30338_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/sj.bjc.6603594","volume":"96","author":"A Thies","year":"2007","unstructured":"Thies, A., Mauer, S., Fodstad, O. & Schumacher, U. Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice. Br J Cancer 96, 609\u2013616 (2007).","journal-title":"Br J Cancer"},{"key":"30338_CR12","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.2002.05.033","volume":"20","author":"A Thies","year":"2002","unstructured":"Thies, A. et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20, 2530\u20132536 (2002).","journal-title":"J Clin Oncol"},{"key":"30338_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neo.2014.05.003","volume":"16","author":"R Ortenberg","year":"2014","unstructured":"Ortenberg, R. et al. CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia 16, 451\u2013460 (2014).","journal-title":"Neoplasia"},{"key":"30338_CR14","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1158\/1535-7163.MCT-11-0526","volume":"11","author":"R Ortenberg","year":"2012","unstructured":"Ortenberg, R. et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Molecular cancer therapeutics 11, 1300\u20131310 (2012).","journal-title":"Molecular cancer therapeutics"},{"key":"30338_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0002-9440(10)61725-7","volume":"159","author":"J Brummer","year":"2001","unstructured":"Brummer, J. et al. cis Interaction of the cell adhesion molecule CEACAM1 with integrin beta(3). The American journal of pathology 159, 537\u2013546 (2001).","journal-title":"The American journal of pathology"},{"key":"30338_CR16","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/S0002-9440(10)63433-5","volume":"165","author":"A Ebrahimnejad","year":"2004","unstructured":"Ebrahimnejad, A. et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. The American journal of pathology 165, 1781\u20131787 (2004).","journal-title":"The American journal of pathology"},{"key":"30338_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-1-61779-854-2_16","volume":"878","author":"D Wicklein","year":"2010","unstructured":"Wicklein, D. RNAi technology to block the expression of molecules relevant to metastasis: the cell adhesion molecule CEACAM1 as an instructive example. Methods Mol Biol 878, 241\u2013250 (2010).","journal-title":"Methods Mol Biol"},{"key":"30338_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102, 1555\u20131577 (2010).","journal-title":"Br J Cancer"},{"key":"30338_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2012.02.019","volume":"321","author":"K Stubke","year":"2012","unstructured":"Stubke, K., Wicklein, D., Herich, L., Schumacher, U. & Nehmann, N. Selectin-deficiency reduces the number of spontaneous metastases in a xenograft model of human breast cancer. Cancer Lett 321, 89\u201399 (2012).","journal-title":"Cancer Lett"},{"key":"30338_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0304-3835(99)00443-7","volume":"152","author":"M Jojovic","year":"2000","unstructured":"Jojovic, M. & Schumacher, U. Quantitative assessment of spontaneous lung metastases of human HT29 colon cancer cells transplanted into SCID mice. Cancer Lett 152, 151\u2013156 (2000).","journal-title":"Cancer Lett"},{"key":"30338_CR21","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1093\/nar\/gni179","volume":"33","author":"M Dai","year":"2005","unstructured":"Dai, M. et al. Evolving gene\/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33, e175 (2005).","journal-title":"Nucleic Acids Res"},{"key":"30338_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","volume":"4","author":"RA Irizarry","year":"2003","unstructured":"Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249\u2013264 (2003).","journal-title":"Biostatistics"},{"key":"30338_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bioinformatics\/19.2.185","volume":"19","author":"BM Bolstad","year":"2003","unstructured":"Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185\u2013193 (2003).","journal-title":"Bioinformatics"},{"key":"30338_CR24","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock, S. J., Clayton, T. C. & Altman, D. G. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359, 1686\u20131689 (2002).","journal-title":"Lancet"},{"key":"30338_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccr.2013.08.018","volume":"24","author":"J Caramel","year":"2013","unstructured":"Caramel, J. et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer cell 24, 466\u2013480 (2013).","journal-title":"Cancer cell"},{"key":"30338_CR26","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-09-0470","volume":"8","author":"N Wajapeyee","year":"2009","unstructured":"Wajapeyee, N., Kapoor, V., Mahalingam, M. & Green, M. R. Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Molecular cancer therapeutics 8, 3009\u20133014 (2009).","journal-title":"Molecular cancer therapeutics"},{"key":"30338_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2007.12.032","volume":"132","author":"N Wajapeyee","year":"2008","unstructured":"Wajapeyee, N., Serra, R. W., Zhu, X., Mahalingam, M. & Green, M. R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363\u2013374 (2008).","journal-title":"Cell"},{"key":"30338_CR28","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/jid.2013.48","volume":"133","author":"V Muthusamy","year":"2013","unstructured":"Muthusamy, V., Premi, S., Soper, C., Platt, J. & Bosenberg, M. The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma. J Invest Dermatol 133, 1827\u20131833 (2013).","journal-title":"J Invest Dermatol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30338-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T08:18:47Z","timestamp":1671610727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30338-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["30338"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-30338-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,8]]},"assertion":[{"value":"10 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11893"}}